Dr. Elissa Lane Freedman, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 23 Liberty Dr, Suite A, Hebron, CT 06248 Phone: 860-228-1119 Fax: 860-228-4314 |
Ann M Sousa, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 105 Main St, Hebron, CT 06248 Phone: 860-228-1119 Fax: 860-228-4314 |
Kristin S. Gildersleeve, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 23 Liberty Dr, Suite A, Hebron, CT 06248 Phone: 860-228-1119 |
Amber Saleem Cheema, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 23 Liberty Dr, Suite A, Hebron, CT 06248 Phone: 860-228-1119 Fax: 860-228-4314 |
News Archive
New analysis shows that while the survivability of wounds on the battlefield has steadily improved for United States service members since World War II, there were several increases that bucked that trend during subsequent conflicts.
Drawing attention to one of the most complex health care bills recently passed by the U.S. Senate, the Society of Actuaries and American Academy of Actuaries today announced the findings from a new technical model and report on the estimated effect of the excise tax on high–cost employer health plans, also known as the "Cadillac Plan" tax. According to the report, while a tax on excess benefits could play a role in offsetting other costs of health reform, specific design elements of the tax may present some issues.
Children delivered by cesarean section and those given antibiotics during early infancy appear more prone to developing allergic inflammation of the esophagus — the muscular tube that connects the mouth to the stomach — according to results of a study by investigators from the Johns Hopkins Children's Center and Harvard Medical School.
Sen. Joe Biden (D-Del.), who is running for the Democratic presidential nomination, in an interview on Sunday on NBC's " Meet the Press " said that he supports a federal law (S 3) banning so-called "partial-birth" abortion but added that the majority opinion in the U.S. Supreme Court's 5-4 decision last month to uphold the law is an "intellectually dishonest rationale for an honest justification for upholding the ban".
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
› Verified 6 days ago